Morgan Stanley Reiterates Overweight Rating on Abbvie (ABBV) Following Healthcare Conference
Tweet Send to a Friend
Morgan Stanley analyst Terrance Flynn reiterated an Overweight rating and $188.00 price target on Abbvie (NYSE: ABBV) after hosting senior ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
